Discover 3,498 paid clinical trials in Torrance, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,498
Active & Responsive
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
for
Lupus Nephritis, Systemic Lupus Erythematosus,
Location: Beverly Hills CA, Fullerton CA, Irvine CA, Fontana CA,
Sponsor: Fate Therapeutics
Sex: All
Age: 12 - 70
Code: NCT07570862
Phase 2, Recruiting
Active & Responsive
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
for
Metastatic Dedifferentiated Liposarcoma,
Location: Los Angeles CA, Pasadena CA, Newport Beach CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06422806
Phase 3, Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: Beverly Hills CA, Los Angeles CA, Duarte CA,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase 3, Recruiting
Active & Responsive
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
for
Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
Location: Beverly Hills CA, Nashville TN, Sarasota FL
Location: Beverly Hills CA, Los Angeles CA, Palo Alto CA,
Sponsor: Pheast Therapeutics
Sex: All
Age: 18+
Code: NCT06840886
Phase 1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
for
Clinical Stage III Cutaneous Melanoma AJCC v8,
Location: Beverly Hills CA, Los Angeles CA, Orange CA, Irvine CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05136196
Phase 2, Recruiting
Active & Responsive
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
for
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: Beverly Hills CA, Los Angeles CA, Topeka KS,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT07441681
Phase 3, Recruiting
Active & Responsive
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
for
Advanced Solid Tumor
Location: Beverly Hills CA, Houston TX, Pittsburgh PA
Sponsor: Strand Therapeutics Inc.
Sex: All
Age: 18+
Code: NCT06249048
Phase 1, Phase 2, Recruiting
Active & Responsive
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
for
Advanced Solid Tumors
Location: Los Angeles CA, San Francisco CA, Aurora CO,
Sponsor: ModernaTX, Inc.
Sex: All
Age: 12+
Code: NCT05533697
Phase 1, Phase 2, Recruiting
Active & Responsive
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
for
Melanoma, Unresectable Melanoma
Location: Los Angeles CA, New York NY, Boston MA
Sponsor: NYU Langone Health
Sex: All
Age: 18 - 70+
Code: NCT05428007
Phase 2, Recruiting
Active & Responsive
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
for
Migraine
Location: Los Angeles CA, Pomona CA, Palm Springs CA, Phoenix AZ,
Sponsor: Mayo Clinic
Sex: All
Age: 18 - 70
Code: NCT06972056
Recruiting
Active & Responsive
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
for
Focal Onset Seizures
Location: Los Angeles CA, Mission Hills CA, West Hills CA,
Sponsor: Supernus Pharmaceuticals, Inc.
Sex: All
Age: 18 - 70
Code: NCT06798896
Phase 2, Recruiting
Active & Responsive
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies